Subsequently, ISO was administered to induce pathological cardiac hypertrophy, and the deletion of Trim44 significantly inhibited the development of pathological hypertrophy and HF, including by improving overall heart morphology and echocardiographic parameters reflecting function, as well as by reducing myocardial fibrosis and hypertrophic cardiac cell size. The gene discussed is TRIM44; the disease is cardiac hypertrophy.